P945: SUBCUTANEOUS ISATUXIMAB ADMINISTRATION BY AN ON-BODY DELIVERY SYSTEM IN COMBINATION WITH POMALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: INTERIM PHASE 1B STUDY RESULTS

• H. Quach,
• G. Parmar,
• E. M. Ocio,
• H. M. Prince,
• A. Oriol,
• N. Tsukada,
• K. Sunami,
• P. Bories,
• C. Karanes,
• S. Madan,
• D. Semiond,
• M. Inchauspe,
• S. Macé,
• P. B. Musholt,
• F. Suzan,
• P. Moreau

Affiliations

H. Quach

1 Clinical Haematology Service, St Vincent’s Hospital, University of Melbourne, Vic

G. Parmar

2 Illawarra Cancer Care Centre, Wollongong, NSW, Australia

E. M. Ocio

3 Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain

H. M. Prince

4 Molecular Oncology and Cancer Immunology, Epworth Healthcare and University of Melbourne, Melbourne, Vic, Australia

A. Oriol

5 Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain

N. Tsukada

6 Department of Hematology, Japanese Red Cross Medical Center, Tokyo

K. Sunami

7 National Hospital Organization Okayama Medical Center, Okayama, Japan

P. Bories

8 Early Phase Unit, Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse, Toulouse, France

C. Karanes

9 Department of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA

S. Madan

10 Banner MD Anderson Cancer Center, Gilbert, AZ

D. Semiond

11 Sanofi, Cambridge, MA, United States of America

M. Inchauspe

12 IT&M Stats for Sanofi, Neuilly sur-Seine

S. Macé

13 Sanofi Research & Development, Chilly-Mazarin, France

P. B. Musholt

14 Sanofi Research & Development, Frankfurt, Germany

F. Suzan

13 Sanofi Research & Development, Chilly-Mazarin, France

P. Moreau

15 Department of Hematology, University Hospital of Nantes, Nantes, France